← back to search

Michael Daskalakis

University of Bern · CH
Area of research
Oncology · Hematology
Research interest
Research interests include CAR-T cell therapy research, Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment, and Epigenetics and DNA Methylation.
h-index
24
citations
2,818
works
112
NIH funding
primary concept
email

Recent publications

CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party
Bone Marrow Transplantation 2025cited by 5position: middledoi
DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts
Nature Communications 2023cited by 85position: middledoi
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
Journal for ImmunoTherapy of Cancer 2023cited by 25position: middledoi
Potential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients with Older Age: Incidence, Mortality, and Survival Rates of Patients with CML in Switzerland from 1995 to 2017
Cancers 2021cited by 8position: firstdoi
Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries
Cancer Epidemiology 2019cited by 16position: middledoi
Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia
Leukemia 2019cited by 15position: middledoi
PF442 TREATMENT WITH 5‐AZACYTIDINE RESULTS IN EXPRESSION OF LONG TERMINAL REPEAT (LTR) ELEMENTS IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH MDS AND AML: FIRST PILOT STUDY
HemaSphere 2019cited by 0position: firstdoi
Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors
Cell Cycle 2018cited by 78position: firstdoi
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats
Nature Genetics 2017cited by 336position: middledoi
Azanucleoside DNA Methyltransferase Inhibitor Drugs: Update on Clinical Applications in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Epigenetics and human health 2016cited by 2position: middledoi
Epigenetic Drug Treatment Globally Induces Cryptic Transcription Start Sites Encoded in Long Terminal Repeats
Blood 2016cited by 0position: firstdoi
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
New England Journal of Medicine 2015cited by 197position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Christoph Plass · German Cancer Research Center4 papers (2018–2023)Gabriela M. Baerlocher · University of Bern3 papers (2015–2021)Ashish Goyal · German Cancer Research Center3 papers (2018–2023)Anita Feller · University of Lucerne2 papers (2019–2021)David Brocks · Immunai (United States)2 papers (2018–2019) · 2 papers (2019–2021)Volker Arndt · German Cancer Research Center2 papers (2019–2021)Mark Hartmann · German Cancer Research Center2 papers (2018–2019)Michael Lübbert · University of Freiburg2 papers (2016–2023) · 2 papers (2015–2019)Jürgen Kuball · Princess Máxima Center1 papers (2025–2025)Christian Chabannon · Institut Pprime1 papers (2025–2025)Olatoyosi Odenike · Leipzig University1 papers (2015–2015) · 1 papers (2019–2019)Alexander Kühn · University Medical Center Freiburg1 papers (2018–2018)Jasmine Noetzli · University of Lausanne1 papers (2021–2021) · 1 papers (2019–2019)Oliver G. Ottmann · Cancer Genetics (United States)1 papers (2015–2015)Simona Pagliuca · Sorbonne Paris Cité1 papers (2025–2025) · 1 papers (2019–2019)